(Q37872295)

24 August 2017

1 reference

title

Antidepressant use in pregnancy (English)

1 reference

24 August 2017

3

Adrienne Einarson

1 reference

24 August 2017

Laura Lorenzo

1

1 reference

24 August 2017

Barbara Byers

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

5 May 2011

1 reference

Expert Opinion on Drug Safety

24 August 2017

published in

1 reference

24 August 2017

volume

10

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

883-889

1 reference

Prevalence of depression during pregnancy: systematic review

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Pharmacokinetic changes during pregnancy and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Pharmacokinetics of sertraline across pregnancy and postpartum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Placental passage of antidepressant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

The principles of teratology: are they still true?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

The safety of antidepressant drugs during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Birth outcomes after prenatal exposure to antidepressant medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Risks associated with selective serotonin reuptake inhibitors in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Newer antidepressants in pregnancy: prospective outcome of a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Delivery outcome in relation to maternal use of some recently introduced antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Maternal use of bupropion and risk for congenital heart defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Use of antidepressants during pregnancy and the risk of spontaneous abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.583917

10.1517/14740338.2011.583917

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference